Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are ...

How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, ...

We've heard how the use of drugs like Ozempic can drive weight loss, as well as potentially boost heart health and cut out ...

Orforglipron, an oral GLP-1 receptor agonist developed by Eli Lilly, has shown positive Phase 3 results in treating type 2 ...

Finding natural ways to increase glucagon-like peptide-1, otherwise known as GLP-1, can be very beneficial in helping treat ...

The rapid increase in the use of glucagon-like peptide-1 receptor agonists for weight loss, diabetes management and ...

Once-daily orforglipron was more effective than placebo and just as safe as injectable GLP-1s in patients with diabetes and ...

Growth is driven by the rising prevalence of diabetes among the elderly, necessitating efficient insulin delivery solutions ...

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

MetaVia (MTVA) announced positive results from the 4-week multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726, a novel, ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of 16 pounds.